A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
Inclusion Criteria:
Exclusion Criteria:
Florianópolis, Santa Catarina 88020-210, Brazil
Nanjing, 210029, China
Shanghai, 200127, China
Moscow, Moscow Oblast 115478, Russia
Moscow, Moscow Oblast 125134, Russia
Moskva, Moscow Oblast 119991, Russia
Santiago de Compostela, LA Coruna 15706, Spain
Pamplona/iruña, Navarre 31008, Spain
Zhongzheng Dist., 10048, Taiwan
Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
Sihhiye/Ankara, 06230, Turkey (Türkiye)